Hypertension in Low and Middle Income Countries

Condition covered
Adults with essential (primary) hypertension

Interventions covered
Pharmacological and non-pharmacological

Details
1 Recorded via the Beliefs about Medicine Questionnaire (BMQ [BMQ-Specific section]).
2 Includes physical activity (recommended to track via the International Physical Activity Questionnaire [IPAQ-Short Form]), medication adherence (recommended to track via the Hill-Bone Compliance to High Blood Pressure Therapy Scale - South Africa Version [Medication taking sub-scale]) and salt intake (recommended to track via the WHO STEPS Instrument).
3 Includes survival (overall and cardiovascular), blood pressure control, hypertensive urgencies and hypertensive emergencies, and erectile function (recommended to track via PROMIS single question).
4 Includes hospitalization, peripheral artery disease, hypertensive crisis, heart failure, ischaemic heart disease, cerebrovascular disease, atrial fibrillation, and renal disease.
5 Recommended to track via one of the following: PROMIS GH-10 v1.2, EQ-5D-3L, WHODAS v2.0, VR-12.

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/
Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsors

The Working Group

Belarus
Vladislav Podpalov | Belarusian Hypertension Society, Vitebsk State Medical University

Brazil
Otavio Berwanger | Hospital do Coração Celso Amodeo | Brazilian Society of Cardiology

Cameroon
Anastase Dzudie Tamdja | Pan African Society of Cardiology, University of Yaounde

Canada
Norman Campbell | University of Calgary

Ernesto Schiffrin | McGill University, Jewish General Hospital

Ghana
Peter Lamprey | London School of Hygiene and Tropical Medicine, FHI 360

India
Raghupathy Anchala | Indian Institute of Public Health Hyderabad, Public Health Foundation of India

Malaysia
Yook-Chin Chia | University of Malaya, Institute for Healthcare Development at Sunway University, Malaysian Society of Hypertension

Mozambique
Albertino Damasceno | Eduardo Mondlane University

Portugal
Manuela Fiuza | Universidade de Lisboa
António Vaz Carneiro | Universidade de Lisboa

Switzerland
Fareed Mirza | Novartis Foundation

United Kingdom
Dorothea Nitsch | London School of Hygiene and Tropical Medicine

United States of America
Gbenga Ogedegbe | New York University Langone Medical Center

Vietnam
Nam Phuong Do Thi | Heart Institute of Ho Chi Minh City

* Two patient representatives from Mexico and Tanzania were also members of the Working Group.

Acknowledgements: We would like to thank the following individuals for their valuable contributions to the project:
Dr. Kolo Philip Manma | University of Ilorin, Nigeria
Dr. Prajwal Pyakurel | B.P. Koirala Institute of Health Sciences, Nepal